[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Chameleon Investor [@InvestChameleon](/creator/twitter/InvestChameleon) on x XXX followers Created: 2025-07-22 18:22:08 UTC Now for what I see as the biggest risk- As $HIMS continues to expand into new categories, they open themselves up to risks associated with these new treatments, especially treatment plans that have less standardized protocols. Providing hair loss treatment is one thing but expanding into testosterone is another. While these new categories have large TAMs, hence why Hims is interested in pursuing them, they inherently carry more risk. These treatments are a lot more complicated when compared to some of Hims current core categories. When there is more potential for things to go wrong for the patient, Hims is higher risk from a legal perspective. They are notorious for allowing customers to get their requested medications with little pushback, therefore Hims would benefit from taking a more prudent approach to prescriptions. With expansion into categories with more risk to adverse side effects that could be far more detrimental, they will need to be careful with how they navigate prescribing these medications. The ongoing care will need much more attention than the foundational categories they have already penetrated.  XXX engagements  **Related Topics** [hims](/topic/hims) [categories](/topic/categories) [$hims](/topic/$hims) [investment](/topic/investment) [hims hers](/topic/hims-hers) [stocks consumer defensive](/topic/stocks-consumer-defensive) [Post Link](https://x.com/InvestChameleon/status/1947723854446821572)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Chameleon Investor @InvestChameleon on x XXX followers
Created: 2025-07-22 18:22:08 UTC
Now for what I see as the biggest risk- As $HIMS continues to expand into new categories, they open themselves up to risks associated with these new treatments, especially treatment plans that have less standardized protocols. Providing hair loss treatment is one thing but expanding into testosterone is another. While these new categories have large TAMs, hence why Hims is interested in pursuing them, they inherently carry more risk. These treatments are a lot more complicated when compared to some of Hims current core categories. When there is more potential for things to go wrong for the patient, Hims is higher risk from a legal perspective. They are notorious for allowing customers to get their requested medications with little pushback, therefore Hims would benefit from taking a more prudent approach to prescriptions. With expansion into categories with more risk to adverse side effects that could be far more detrimental, they will need to be careful with how they navigate prescribing these medications. The ongoing care will need much more attention than the foundational categories they have already penetrated.
XXX engagements
Related Topics hims categories $hims investment hims hers stocks consumer defensive